The primary focus of MTL is the collaborative creation, adaptation and use of state-of-the-art biomolecular screening technologies to discover compounds (including non-peptidic, peptidic and proteinaceous compounds) that selectively interact with or modify functions of specific molecular targets (e.g., endogenous molecules, structures, processes or pathways) of priority interest to the CCR, NCI. Tangible products of these efforts include novel or known compounds that may be used as "bioprobes" for target validation research or as drug discovery leads or templates. Accordingly, collaborative research opportunities include the following:
- Biomolecular Assay Development
- High Throughput Screening (HTS)
- Natural Products
- External Compound Libraries
- Other Discovery Tools
© 2000-2017 Center for Cancer Research at the National Cancer Institute.
questions, comments, and suggestions to webmaster